Repare Therapeutics

Repare Therapeutics Inc., a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair. Its lead product candidate is RP-3500, an oral small molecule inhibitor for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing RP-6306, which is under Phase I clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; and Polymerase Theta program, a SL target associated with BRCA mutations and other genomic alterations. The company was incorporated in 2016 and is headquartered in Montreal, Canada.

To transform the way tumor biology is understood, and to revolutionize the way cancer is treated.

To become a leader in precision oncology, driving the development of transformative therapies, and improving the lives of our patients.

Repare Therapeutics has received numerous awards, including the 2020 Prix PME Québec Prix and a 2020 Bio Award. The company was also recognized by Nature Biotechnologies as a 2020 Biotech of the Year Finalist.